title: Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.
abstract: With the introduction of varicella vaccination, surveillance of varicella-zoster virus (VZV) strains occurring in cases of chickenpox or zoster should be considered. Differentiating Oka vaccine strain from wild-type VZV can be achieved only using molecular genotyping. In the present study, the VZV genotype was examined in 53 VZV strains isolated from patients with varicella or zoster and in 73 samples from skin eruptions, cerebrospinal fluid, and throat swabs obtained from patients with VZV infections in Germany. The polymerase chain reaction and restriction fragment length polymorphisms analysis using DNA fragments of the open reading frames 38, 54, 62, and the R5 repeat region were used. Whereas all VZV isolates could be typed, direct genotyping of viral DNA in patients' samples was achieved in 63 of 73 cases (86.3%). The dominant genotype of VZV found in 88.8% of 116 patients had the wild-type pattern PstI(+) BglI(-) R5A followed by the wild-genotype PstI(+) BglI(+) R5A in 6.0%, the wild-genotype PstI(+) BglI(-) R5B in 3.4%, the wild-genotype PstI(+) BglI(-) R5C and the Oka vaccine genotype PstI(-) BglI(+) R5B in 0.9% of patients each. BglI(-) wild-types were found in 90.7% of patients with zoster and in 9.3% of patients with varicella. By contrast, the BglI(+) wild-type was diagnosed in five patients with varicella and in two patients with zoster. In conclusion, VZV strains found in Germany are similar to strains circulating in the United States and the United Kingdom. VZV wild-type strains containing a BglI restriction site in ORF 54 as well as Oka vaccine strains can rarely be detected.
authors.affiliation: Institute of Virology and Therapy, Friedrich-Schiller University of Jena, Jena, Germany. Andreas.Sauerbrei@med.uni-jena.edu
authors.forename: A
authors.initials: A
authors.lastname: Sauerbrei
authors.forename: U
authors.initials: U
authors.lastname: Eichhorn
authors.forename: S
authors.initials: S
authors.lastname: Gawellek
authors.forename: R
authors.initials: R
authors.lastname: Egerer
authors.forename: M
authors.initials: M
authors.lastname: Schacke
authors.forename: P
authors.initials: P
authors.lastname: Wutzler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002644:Chickenpox / Q000453:epidemiology* / Q000821:virology; D019433:Chickenpox Vaccine; D002648:Child; D002675:Child, Preschool; D005260:Female; D005838:Genotype; D005858:Germany / Q000453:epidemiology; D006562:Herpes Zoster / Q000453:epidemiology / Q000821:virology; D014645:Herpesvirus 3, Human / Q000145:classification* / Q000235:genetics*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D017720:Molecular Epidemiology; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length
chemical_list: D019433:Chickenpox Vaccine